This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
by Ekta Bagri
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
NVSNegative Net Change BMYNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
by Kanishka Das
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
PFENo Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechs
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
by Zacks Equity Research
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
BCRXPositive Net Change IONSPositive Net Change KALVPositive Net Change PHVSPositive Net Change
biotechs medical
BMY Gains on News of Continuation of Alzheimer's Disease Study
by Zacks Equity Research
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
BMYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
by Zacks Equity Research
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
ZTSPositive Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
by Sundeep Ganoria
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
JNJNegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case
by Zacks Equity Research
Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.
JNJNegative Net Change BAYRYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
by Zacks Equity Research
Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
PCRXNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
by Zacks Equity Research
AstraZeneca's NDA for baxdrostat gains FDA priority review for treating hard-to-control hypertension. A decision is due in the second quarter of 2026.
AZNPositive Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechs
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
by Ahan Chakraborty
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechs pharmaceuticals
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
by Zacks Equity Research
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGNNegative Net Change RHHBYPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
by Zacks Equity Research
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
FOLDNegative Net Change ANIPPositive Net Change CRMDPositive Net Change BHCNo Net Change
biotechnology biotechs medical pharmaceuticals
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
by Zacks Equity Research
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
PFENo Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
by Zacks Equity Research
Mirum enrolls the first participant in its phase II BLOOM study investigating MRM-3379 for treating Fragile X syndrome.
CRMDPositive Net Change ADMAPositive Net Change MIRMPositive Net Change ARQTNegative Net Change
biotechs
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
by Sundeep Ganoria
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
PFENo Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change PCVXPositive Net Change
biotechs messenger-rna pharmaceuticals vaccines
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYNegative Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
by Zacks Equity Research
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
ARCTNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
AZNPositive Net Change PFENo Net Change LLYPositive Net Change AMGNNegative Net Change
biotechs
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
REGNNegative Net Change SNYNegative Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
by Sundeep Ganoria
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
PFENo Net Change NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Biotech ETF (BBC) Hits New 52-Week High
by Sanghamitra Saha
Biotech ETF BBC hits a 52-week high amid renewed sector momentum, Fed rate cuts and AI-driven healthcare gains, hinting at more near-term upside.
BBCPositive Net Change
biotechs etfs
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
by Sundeep Ganoria
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
ANIPPositive Net Change AMRXPositive Net Change
biotechs medical
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
by Kanishka Das
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
REGNNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechs
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
by Ekta Bagri
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
BMYNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals